Rubaida Mehmood, Sabika Rafiq, Momna Warraich, Dr.Daniyal Warraich, Rida Sana, Dr Rubina Mukhtar, Dr Sidrah Mahmood Ali



Background: The pathogenesis of liver function abnormalities and cardiac dysfunction in hyperthyroid patients after I131 treatment is still unclear. The aim of this study was to determine the effects of radioiodine I131 on liver function parameters, lactate dehydrogenase(LDH) and low-density lipoproteins(LDL) before and after I131 therapy in hyperthyroidism patients.

Method: Total 52 patients of hyperthyroidism recommended for I131were involved in this study with age ranging from 12–65 years (mean age=38.6±14.8 & BMI=11.5±3.7). The significance of the differences between the results of 1st, 2nd and 3rd time serum analysis was assessed by unpaired student’s t-test. Associations between the parameters were assessed by Spearman correlation analysis. 

Results: Significant variations were observed for thyroid profile FT3(p=0.04), FT4(p=0.01), TSH(p=0.005) during the follow-up treatment. Before taking I131 (serum analyzed at 1st time), negative correlation of FT3 with AST (r=-0.458, p=0.032) and LDL (r=-0.454, p=0.039) were observed. During 2nd time (after stopping carbimazole) no correlation were assessed. Two months after administration of I131 drops, significant negative association of FT3 (r=-0.62, p=0.04) and FT4(r=-0.61, p=0.02) with ALB were observed. FT3(r=-0.82, p=0.00) & FT4 (r=-0.71, p=0.00) also showed negative correlation with LDL after I131 therapy. Whereas TSH showed significant positive association with ALB (r=0.61, p=0.01) and LDL (r=0.70, p=0.00) respectively.

Conclusion: Our findings suggest that the association of TFTs with biochemical parameters in patients with goiter recommended for iodine therapy is an important diagnostic and therapeutic tool.  The increase in transaminases and LDL level after administration of I131 therapy may adversely affect heart and liver function.

Full Text:




Kopp, P., Thyrotoxicosis of other etiologies, in Endotext [Internet]. 2010, MDText. com, Inc.

Klein, I. and K. Ojamaa, Thyrotoxicosis and the heart. Endocrinology and metabolism clinics of North America, 1998. 27(1): p. 51-62.

Taylor, P.N., et al., Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology, 2018. 14(5): p. 301.

Matovinovic, J., Endemic goiter and cretinism at the dawn of the third millennium. Annual review of nutrition, 1983. 3(1): p. 341-412.


Testa, R.M., S. Martinelli, and F. Pacini, Diagnosis and Treatment of Hyperthyroidism, in Clinical Applications of Nuclear Medicine Targeted Therapy. 2018, Springer. p. 3-17.

Vanderpump, M., et al., The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey. Clinical endocrinology, 1995. 43(1): p. 55-68.


Canaris, G.J., et al., The Colorado thyroid disease prevalence study. Archives of internal medicine, 2000. 160(4): p. 526-534.

Alam Khan, V., M.A. Khan, and S. Akhtar, Thyroid disorders, etiology and prevalence. J Med Sci, 2002. 2(2): p. 89-94.

Elias, R.M., D.S. Dean, and G.W. Barsness, Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience. ISRN endocrinology, 2012. 2012.

Mebis, L., L. Langouche, and G. Van den Berghe, Changes within the thyroid axis during the course of critical illness, in Acute Endocrinology. 2008, Springer. p. 199-213.

Biscoveanu, M., Michaela and M. Hasinski, FACE, FACP, Stefan, ABNORMAL RESULTS OF LIVER FUNCTION TESTS IN PATIENTS WITH GRAVES'DISEASE. Endocrine Practice, 2000. 6(5): p. 367-369.

Upadhyay, G., et al., Severe hyperthyroidism induces mitochondria‐mediated apoptosis in rat liver. Hepatology, 2004. 39(4): p. 1120-1130.

Khemichian, S. and T.-L. Fong, Hepatic dysfunction in hyperthyroidism. Gastroenterology & hepatology, 2011. 7(5): p. 337.

Hassi, J., et al., The pituitary-thyroid axis in healthy men living under subarctic climatological conditions. Journal of endocrinology, 2001. 169(1): p. 195.

LARSEN, P.R., Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content. The Journal of Clinical Endocrinology & Metabolism, 1975. 41(6): p. 1098-1104.

Inkinen, J., J. Sand, and I. Nordback, Association between common bile duct stones and treated hypothyroidism. Hepato-gastroenterology, 2000. 47(34): p. 919-921.

Thompson, W.G. and I.R. Hart, Chronic active hepatitis and Graves' disease. The American journal of digestive diseases, 1973. 18(2): p. 111-119.

Ponsin, G., C. Vialle-Valentin, and F. Berthezene, Alterations of high density lipoproteins induced by thyroid hormones in man and rat, in Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics. 1990, Springer. p. 147-154.

Brent, G.A., Graves' disease. New England Journal of Medicine, 2008. 358(24): p. 2594-2605.

Hollenberg, A.N., The role of the thyrotropin-releasing hormone (TRH) neuron as a metabolic sensor. Thyroid, 2008. 18(2): p. 131-139.

Liberopoulos, E.N. and M.S. Elisaf, Dyslipidemia in patients with thyroid disorders. HORMONES-ATHENS-, 2002. 1: p. 218-223.

Chang, H.-J., et al., Endothelial function is not changed during short-term withdrawal of thyroxine in patients with differentiated thyroid cancer and low cardiovascular risk. Yonsei medical journal, 2010. 51(4): p. 492-498.

Duntas, L.H. and G. Brenta, The effect of thyroid disorders on lipid levels and metabolism. Medical Clinics, 2012. 96(2): p. 269-281.

Oszukowska, L., M. Knapska-Kucharska, and A. Lewiński, Effects of drugs on the efficacy of radioiodine (131|) therapy in hyperthyroid patients. Archives of medical science: AMS, 2010. 6(1): p. 4.

Isgoren, S., et al., Radioiodine therapy in Graves’ disease: Is it possible to predict outcome before therapy? Nuclear medicine communications, 2012. 33(8): p. 859-863.

Cooper, D.S., Antithyroid drugs. New England Journal of Medicine, 2005. 352(9): p. 905-917.

Association, A.T., et al., Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 2011. 21(6): p. 593-646.

Mehmood, R., et al., Evaluation of di‐potassium and tri‐potassium EDTA evacuated tubes for routine haematological testing. Journal of clinical laboratory analysis, 2018. 32(1): p. e22188.

Watters, D.A.K. and J. Wall, Thyroid surgery in the tropics. ANZ journal of surgery, 2007. 77(11): p. 933-940.

Meng, Z., et al., Evaluation of serum midkine as a biomarker in differentiated thyroid cancer. Life sciences, 2015. 130: p. 18-24.

Kano, T., et al., Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices. Gastroenterologia Japonica, 1987. 22(3): p. 344-353.

Parle, J., et al., Circulating lipids and minor abnormalities of thyroid function. Clinical endocrinology, 1992. 37(5): p. 411-414.

Jabuk, S.K., A.H. Alta'ee, and F.A. Alterihy, The association between thyroid hormones and lipid profile in patients with primary hyperthyroidism. Medical Journal of Babylon, 2012. 9(4): p. 721-727.

Shakhreet, B., et al., The Role of Radioactive Iodine in Thyrotoxicosis Patients. Current Journal of Applied Science and Technology, 2015: p. 1-7.

Mehmood, R., et al., Monitoring and Evaluation of Thyroid Function Tests, Serum Electrolytes and Creatinine Levels Before and After 131I Therapy. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 2020. 20(3): p. 419-424.

Alavi, M., et al., Evaluation of a Number of Blood Biochemical Markers after Radioiodine Therapy in Papillary Thyroid Cancer Patients. Middle East Journal of Cancer, 2017. 8(2).

Papachristos, D.A., et al., Liver dysfunction and anti-thyroid therapy. SAGE open medical case reports, 2015. 3: p. 2050313X14568335.

Wang, R., et al., Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of 131iodine treatment. Medicine, 2017. 96(5).

Desai, R., et al., Thyroid function in hospitalized patients: effect of illness and serum albumin concentrations. Clinical chemistry, 1987. 33(8): p. 1445-1447.

Du, X., et al., Albuminuria is an independent risk factor of T4 elevation in chronic kidney disease. Scientific reports, 2017. 7(1): p. 1-7.

Azizi, F., et al., Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. European journal of endocrinology, 2005. 152(5): p. 695-701.

Muls, E., et al., Serum lipids and apolipoproteins AI, A-II, and B in hyperthyroidism before and after treatment. The Journal of Clinical Endocrinology & Metabolism, 1982. 55(3): p. 459-464.

Costantini, F., et al., Effect of thyroid function on LDL oxidation. Arteriosclerosis, thrombosis, and vascular biology, 1998. 18(5): p. 732-737.

Tunbridge, W., et al., Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. Clinical endocrinology, 1977. 7(6): p. 495-508.

Pucci, E., L. Chiovato, and A. Pinchera, Thyroid and lipid metabolism. International Journal of Obesity, 2000. 24(2): p. S109-S112.

Åsvold, B.O., et al., The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. European journal of endocrinology, 2007. 156(2): p. 181-186.

Rizos, C., M. Elisaf, and E. Liberopoulos, Effects of thyroid dysfunction on lipid profile. The open cardiovascular medicine journal, 2011. 5: p. 76.


  • There are currently no refbacks.

© Copyright PJR 2008-